Rznomics Inc. (KOSDAQ:476830)

South Korea · Delayed Price · Currency is KRW

40,750

-2,200 (-5.12%)

At close: Jun 26, 2026

-54.72% (1Y)

Market Cap	1.25T
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	27.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	394,246
Open	43,150
Previous Close	42,950
Day's Range	40,050 - 44,250
52-Week Range	40,050 - 245,250
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Rznomics

Rznomics Inc. develops RNA based gene therapies for cancers and intractable diseases. Its development stage product candidates include RZ-001_immune therapy combination product, which is in Phase 1b/2a stage for treating Hepatocellular carcinoma; RZ-001 (GBM) that is in Phase 1/2a stage for Glioblastoma; RZ-003, which is in discovery stage for Alzheimer; RZ-004, a pre-clinical product for Retinitis Pigmentosa; and RZ-005, a discovery stage product to treat Rett Syndrome. Rznomics Inc. was incorporated in 2017 and is headquartered in Seongnam-si... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2017

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 476830

Full Company Profile